(Editor's Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
iCo Therapeutics (ICO.V) (OTCQX:ICOTF) is a small cap Canadian biotechnology company focused on the development of novel therapeutics for the treatment of ophthalmologic and infectious diseases. The company's lead development candidate is iCo-007, a second generation antisense drug for the treatment of diabetic macular edema. The completion of enrollment for the 208 patient iDEAL trial was announced in June 2013, and top-line results are expected in the first quarter of 2014.
Our interest in iCo Therapeutics follows in part from our previous survey, which found a high level of Phase II clinical success associated with locally administered antisense drugs.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|